SEC Comment Letter 0000000000-24-010041 to BeOne Medicines Ltd. (BEIGF)

BeOne Medicines Ltd.
Date: Sept. 5, 2024 · CIK: 0001651308 · Accession: 0000000000-24-010041

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-37686

Date

September 5, 2024

Author

John V. Oyler

Form

UPLOAD

Company

BeOne Medicines Ltd.

Letter

September 5, 2024 John V. Oyler Chief Executive Officer BeiGene, Ltd. 94 Solaris Avenue, Camana Bay Grand Cayman Cayman Islands KY1-110 Re:BeiGene, Ltd. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 26, 2024 File No. 001-37686 Dear John V. Oyler: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Edwin O’Connor, Esq.

Show Raw Text

September 5, 2024
John V. Oyler
Chief Executive Officer
BeiGene, Ltd.
94 Solaris Avenue, Camana Bay
Grand Cayman
Cayman Islands KY1-110
Re:BeiGene, Ltd.
Form 10-K for the Fiscal Year Ended December 31, 2023
Filed February 26, 2024
File No. 001-37686
Dear John V. Oyler:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Edwin O’Connor, Esq.

SecProbe.io